Oral contraceptives and thrombosis

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 4, 2000, Pages 296-300

  Carter, Cedric J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ACTIVATED PROTEIN C RESISTANCE; DRUG FORMULATION; HUMAN; HYPERCOAGULABILITY; ORAL CONTRACEPTION; PATIENT SELECTION; REVIEW; RISK BENEFIT ANALYSIS; VEIN THROMBOSIS;

EID: 0033925361     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200007000-00008     Document Type: Review

References (32)

1. 1 Inman WHW, Vessey MP, Westerholm B, Engelund A: Thromboembolic diseases and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 1970, 2:203-209.
2. 2 Gerstman BB, Piper JM, Tomita DK, et al.: Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991, 133:32-37.
3. 3 Bottinger LE, Boman G, Eklund G, Westerholm B: Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980, 1:1097-1101.
4. 4 Douketis JD, Ginsberg JS, Holbrook A, et al.: A reevaluation of the risk of venous thromboembolism with the use of oral contraceptives and hormonal replacement therapy. Arch Intern Med 1997, 157:1522-1530.
5. 5 Douketis JD, Kearon C, Bates S, et al.: Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998, 279:458-462.
6. 6 Mellemkjaer L, Sorensen HT, Dreyer L, et al.: Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark. Br Med J 1999, 319:820-821.
7. 7 World Health Organization: World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives; results of an international multicentre case-control study. Lancet 1995, 346:1575-1582.
8. 8 World Health Organization: World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995, 346:1582-1588.
9. 9 Jick H, Jick SS, Gurewich V, et al. C: Risk of idiopathic cardiovascular disease and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995, 346:1589-1593.
10. 10 Spitzer WO, Lewis MA, Heinemann LAJ, et al.: Third generation oral contraceptives and risk of venous thromboembolic disease: an international case-control study. Br Med J 1996, 312:83-88.
11. 11 Lewis MA, Heinemann LAJ, MacRae KD, et al.: The increased risk of venous thromboembolism and the use of third generation progestogens: role of bias in observational research. Contraception 1996, 54:5-13.
12. 12 Suissa S, Biais L, Spitzer WO, et al.: First time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997, 56:141-146.
13. 13 Farmer RDT, Lawrenson RA, Thompson CR, et al.: Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997, 349:83-88.
14. 14 Lidegaard O: The influence of thrombotic risk when oral contraceptives are prescribed. Acta Obstet Gynecol Scand 1997, 76:252-260.
15. 15 Heinemann LAJ, Lewis MA, Assmann A, et al.: Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with oral contraceptives? Pharmacoepidemiol Drug Safety 1996, 5:285-294.
16. 16 Dunn N, White I, Freemantle S, Mann RD: The role of prescribing and referral bias in studies of the association between third generation contraceptives and increased risk of thromboembolism. Pharmacoepidemiol Drug Safety 1998, 7:3-14.
17. 17 Lidegaard O, Edstrom B, Kreiner S: Oral contraceptives and venous thromboembolism: a case control study. Contraception 1998, 57:291-301.
18. 18 Herings RM, Urquart J, Leufkens HG: Venous thromboembolism among new users of different oral contraceptives. Lancet 1999, 354:127-128.
19. 19 Jick H, Jick SS: Third generation oral contraceptives and venous thrombosis [letter]. Lancet 1997, 349:731-732.
20. 20 Poulter NR, Chang CL, Marmot M, et al.: Third generation oral contraceptives and venous thrombosis [letter]. Lancet 1997, 349:732.
21. 21 Parley TMM, Meirik O, Marmot MG, et al.: Oral contraceptives and risk of venous thromboembolism: impact of duration of use [letter]. Contraception 1998, 57:61-64.
22. 22 Vandenbrouke JP, Bloemenkamp KWM, Heimerhorst FM, Rosendaal FR: Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands [letter]. Lancet 1996, 348:401-402.
23. 23 Thomas SHK: Mortality from venous thromboembolism and myocardial infarction in young adults in England and Wales [letter]. Lancet 1996, 348:402.
24. 24 Beral V, Hermon C, Kay C, et al.: Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study. Br Med J 1999, 318:96-100. The significance of this paper is the global examination of all the medical aspects of the OC.
25. 25 Dahlback B, Carlsonn M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993, 90:1004-1008.
26. 26 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995, 85:1504-1508.
27. 27 Vandenbrouke JP, Koster T, Briet E, et al.: Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994, 344:1453-1457.
28. 28 Rosing J, Middeldorp S, Curvers J, et al.: activated protein C: a randomised cross-over study. Lancet 1999, 354:2036-2040.
29. 29 Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 1999, 353:1167-1173. This is probably the best article explaining the concept of cumulative thrombotic risks in the development of VTE.
30. 30 Martinelli I, Sacchi E, Landi G, et al.: High risk of cerebral-vein thrombosis in carriers of prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998, 338:1793-1797.
31. 31 Walker AM: Newer oral contraceptives and the risk of venous thromboembolism. Contraception 1998, 57:169-181.
32. 32 O'Brien PA: The third generation oral contraceptive controversy: The evidence shows they are less safe than second generation pills [editorial]. Br Med J 1999, 319:795-796.